Key facts
- Pentas’s last known valuation is $43.6M (Sep 2025).
- It has raised $5.0M; the latest was Later Stage VC ($5.0M) in Sep 2025.
- Notable investors include XTech Ventures, WM PARTNERS (Tokyo), Fast Track Initiative, NES Venture Capital, Valueup Partners.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Pentas
- ·The full record, as it builds
Funding rounds
No funding rounds for Pentas are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pentas
Manufacturer of medical devices intended for treating cerebral vascular conditions. The company's platform includes metal stents and specialized delivery microcatheters, along with preoperative simulation software designed to visualize and optimize stent placement, enabling the neuroendovascular therapy market to perform safer, more accurate procedures that improve patient outcomes and support effective stroke treatment.
- Sector
- Healthcare
- HQ
- Kawasaki, Japan
- Founded
- 2015
- Employees
- 10
- Website
- pentas-medical.jp/
- Ownership
- Privately Held (backing)
Pentas doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pentas shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pentas in its N-PORT filings yet. We sweep new filings monthly.